Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig ™ (erenumab) For Migraine Patients With Multiple Treatment Failures

The LIBERTY Trial was Conducted in Patients who Have Tried Two to Four Therapies Without Success -- a Uniquely Difficult-to-Treat Population Often Excluded From Migraine Prevention Trials Patients Taking Aimovig had Nearly Three-Fold Higher Odds of Having Their Migraine Days cut by Half or More Compared to Placebo Safety and Tolerability Were Consistent With Results Seen in the Pivotal Clinical Program; Over 97 Percent of Those Taking Aimovig Completed the Double-Blind Treatment Phase Data Selected by the American Academy of Neurology Science Committee as one of the Most Noteworthy Presentations at 2018 Annual Meeting THOUSAND OAKS, Calif., April 17, 2018 /PRNewswire/ -- Amgen (NA...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Related Links:

Findings, published inFrontiers in Molecular Biosciences, indicate that women are more likely to suffer migraines due to the action of oestrogen on the cranial nerves.Medical News Today
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
ConclusionsTo the best of our knowledge, it is the first case reported in the literature of a patient who has been affected by recurrent non-functional pituitary adenoma and medullary thyroid carcinoma, concomitantly. Although this association can be accidental, it emphasizes the fact that patients with a history of a neoplasm should be monitored regularly in order to diagnose and treat possible second primary cancers in a timely manner. Of note, this consideration is of great importance in patients whose first neoplasms have better prognosis and survival rates, which provide them more time to develop second primary cancer...
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
The purpose of this study was to compare pericranial tenderness of females with episodic cervical headache vs matched asymptomatic controls.
Source: Journal of Manipulative and Physiological Therapeutics - Category: Complementary Medicine Authors: Source Type: research
ConclusionDFN-11 was effective, tolerable, and safe in the acute treatment of 4 migraine attacks over 8  weeks, with consistent responses on pain and associated symptoms. Most TEAEs were mild, with a very low incidence of triptan-related TEAEs. DFN-11 is potentially an effective and safe alternative for the acute treatment of migraine.Trial registrationClinicalTrials.gov,NCT02569853. Registered 07 October 2015.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
ConclusionsThis study met its primary endpoint, pain freedom at 2  h postdose, with DFN-11 significantly better than placebo, and the incidence of TEAEs and triptan sensations with DFN-11 was low. The 3 mg dose of sumatriptan in DFN-11 appears to be an effective alternative to a 6 mg SC dose of sumatriptan, with good safety and tolerability. (clinicaltrials.gov: NCT02569853; registered 07 October 2015).
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
Authors: Choy M Abstract Lofexidine hydrocholoride (Lucemyra) for opioid withdrawal; erenumab-aooe (Aimovig) for migraine; and sodium zirconium cyclosilicate (Lokelma) for hyperkalemia. PMID: 30100686 [PubMed]
Source: P and T - Category: Drugs & Pharmacology Tags: P T Source Type: research
Results of new research suggest that changing levels of the female sex hormone estrogen make cells around a key nerve in the head and connected blood vessels more sensitive to migraine triggers, scientists say. And that increases migraine risk.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Cristiano Termine, Beatrice Bartoli, Massimo A. Agosti, Andrea E. Cavanna, Umberto Balottin
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Publication date: Available online 14 August 2018Source: Epilepsy &BehaviorAuthor(s): Pasquale Parisi, Vincenzo Belcastro, Alberto Verrotti, Pasquale Striano, D.G.A. Kasteleijn-Nolst Trenitè
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
MCR Safety has released new lens technology that is capable of blocking 41% of ISO 12312-1 blue light while allowing 88% of all visible light to pass in their new MAXBLUE™ VL210MB safety glasses. Blue light is known to cause eye fatigue, headaches and migraines in people exposed to RF scanners and other handheld or portable devices on the job. The lenses are clear with a streamline, comfortable and athletic design. They are scratch resistant with a polycarbonate frame.This story is related to the following:Safety&Security EquipmentHealth, Medical,&Dental Supplies and EquipmentSearch for suppliers of:Lenses |Eyewear Lenses |
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news
More News: Academies | Brain | Headache | Migraine | Neurology | Neuroscience | Pharmaceuticals | Science